Literature DB >> 2541365

The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride.

G P Luscombe1, R H Hopcroft, P C Thomas, W R Buckett.   

Abstract

Sibutramine HCl is an inhibitor of the reuptake of monoamines with a pharmacological profile in rodents indicative of antidepressant activity. The secondary (BTS 54 354) and primary (BTS 54 505) amine metabolites of the tertiary amine sibutramine HCl exhibit similar in vivo pharmacological activity to the parent compound. Thus, each compound displays potent activity in acute behavioural models predictive of antidepressant effects and a comparable ability to inhibit the uptake of monoamines in vivo. In addition, BTS 54 354 and BTS 54 505 induce an equally rapid and potent down-regulation of cortical beta-adrenoceptors in the rat as sibutramine HCl. The secondary and primary amines are, however, considerably more active than sibutramine HCl as inhibitors of the uptake of noradrenaline, dopamine and 5-hydroxytryptamine in vitro. The potent inhibition of the reuptake of noradrenaline by the secondary and primary amine metabolites probably contributes to the rapid and potent down-regulation of beta-adrenoceptors in the rat, induced by the putative antidepressant sibutramine HCl.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541365     DOI: 10.1016/0028-3908(89)90048-8

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  15 in total

1.  Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats.

Authors:  G Grignaschi; E Fanelli; I Scagnol; R Samanin
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl.

Authors:  G P Luscombe; N A Slater; M B Lyons; R D Wynne; M L Scheinbaum; W R Buckett
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Thermogenic effects of sibutramine and its metabolites.

Authors:  I P Connoley; Y L Liu; I Frost; I P Reckless; D J Heal; M J Stock
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

4.  Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers.

Authors:  K A Wesnes; C Garratt; M Wickens; A Gudgeon; S Oliver
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

5.  A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine.

Authors:  D J Heal; A T Frankland; J Gosden; L J Hutchins; M R Prow; G P Luscombe; W R Buckett
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Experience (mostly negative) with the use of sympathomimetic agents for weight loss.

Authors:  Mario A Inchiosa
Journal:  J Obes       Date:  2010-08-12

7.  Effects of sibutramine on the central dopaminergic system in rodents.

Authors:  T Nakagawa; K Ukai; T Ohyama; Y Gomita; H Okamura
Journal:  Neurotox Res       Date:  2001-07       Impact factor: 3.911

Review 8.  Sibutramine. A review of its contribution to the management of obesity.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

9.  Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: a PET study using (11)C-DASB in healthy humans.

Authors:  Peter S Talbot; Stefan Bradley; Cyril P Clarke; Kola O Babalola; Andrew W Philipp; Gavin Brown; Adam W McMahon; Julian C Matthews
Journal:  Neuropsychopharmacology       Date:  2009-11-04       Impact factor: 7.853

10.  Differences in the mechanisms that increase noradrenaline efflux after administration of d-amphetamine: a dual-probe microdialysis study in rat frontal cortex and hypothalamus.

Authors:  Sandrine M Géranton; David J Heal; S Clare Stanford
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.